Phase 1 PK Study of Cediranib in Single and Multiple Doses in Hepatically Impaired Patients With Solid Tumours
- Registration Number
- NCT00621725
- Lead Sponsor
- AstraZeneca
- Brief Summary
To determine how patients with advanced cancer and various degrees of hepatic impairment will metabolise Cediranib.
- Detailed Description
Not available
Recruitment & Eligibility
- Status
- COMPLETED
- Sex
- All
- Target Recruitment
- 36
Inclusion Criteria
- Written informed consent
- Advanced solid tumour (not prostate cancer) for which no standard therapy exists
- WHO performance status 0-2
- Bilirubin levels within the target range
Read More
Exclusion Criteria
- Unstable brain/meningeal metastases
- Inadequate bone marrow reserve
- Biochemistry/haematology results outside of required ranges
- History of significant GI impairment
Read More
Study & Design
- Study Type
- INTERVENTIONAL
- Study Design
- PARALLEL
- Arm && Interventions
Group Intervention Description 1 AZD2171 -
- Primary Outcome Measures
Name Time Method To assess the single dose pharmacokinetics (PK) of Cediranib, in patients with cancer with various degrees of hepatic dysfunction (defined by bilirubin levels). Single dose PK assessed on Day 1 of dosing
- Secondary Outcome Measures
Name Time Method Safety/tolerability of Cediranib (single and multiple dose PK) assessed from randomisation to data cut-off (15th July 2010) Single and multiple dose PK assessed on Day 1 of the single dosing period and Day 21 of the multiple dosing period, respectively (minimum 7 day washout following single dosing)
Trial Locations
- Locations (1)
Research Site
🇳🇱Rotterdam, Netherlands